Rafferty Asset Management
TRVI icon

Rafferty Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Rafferty Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276K Buy
14,824
+2,536
+21% +$36.9K ﹤0.01% 1027
2026
Q1 		$147K Sell
12,288
-4,211
-26% -$47.1K ﹤0.01% 1038
2025
Q4 		$207K Buy
16,499
+2,933
+22% +$33.9K ﹤0.01% 1100
2025
Q3 		$124K Buy
13,566
+2,583
+24% +$19.4K ﹤0.01% 1092
2025
Q2 		$60.1K Buy
+10,983
New +$68.3K ﹤0.01% 1073

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Rafferty Asset Management's TRVI Position: Q2 2026 in Review

Rafferty Asset Management increased its Trevi Therapeutics (TRVI) stake by 21% in Q2 2026, buying an estimated $36.9K and bringing the position to 14,824 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #1027.

Rafferty Asset Management first reported a position in TRVI in Q2 2025 and has held it in 5 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Rafferty Asset Management held 14,824 shares of Trevi Therapeutics worth $276K as of Q2 2026.
  • Rafferty Asset Management bought 2,536 Trevi Therapeutics shares in Q2 2026, an estimated $36.9K.
  • Trevi Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1027 holding.
  • Rafferty Asset Management first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.